Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03737838 · ClinicalTrials.gov registry record
Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 29
- Enrollment target
NCT03737838 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 29 participants.
The verdict
NCT03737838 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to perform ultra-high density mapping of the left atrium (a chamber of the heart) using the the Rhythmia Mapping System and to determine whether additional ablation in areas of wavefront discontinuities identified by the map will reduce the likelihood of both atrial fibrillation and atrial flutter.
Interventions
- DEVICE Atrial fibrillation ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2021-02-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03737838
The ClinicalTrials.gov registry entry for NCT03737838 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atrial fibrillation ablation is the first listed.
NCT03737838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03737838 about?
NCT03737838 is a clinical study titled "Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)". The purpose of this study is to perform ultra-high density mapping of the left atrium (a chamber of the heart) using the the Rhythmia Mapping System and to determine whether additional ablation in areas of wavefront discontinuities identified by the map will reduce the likelihood of both atrial fibr...
What is the current status of trial NCT03737838?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2018-10-31. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT03737838?
The interventions under investigation include: Atrial fibrillation ablation (DEVICE).
Who is sponsoring clinical trial NCT03737838?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.